The ACR and a new Access to Reproductive Health Care Task Force are working to ensure patients with rheumatic disease—particularly women—have access to the medications and treatments they need, including methotrexate, and that rheumatology providers are able to maintain trusting relationships with and advise their patients on all matters relevant to the management of their rheumatic diseases.
Does anyone know why the band Fleetwood Mac might have been an expert in medical communication? Physicians and other medical providers have multiple roles; one obvious task is to provide advice. And for this advice to be valuable, we need to be good listeners; we need to absorb data from multiple sources, which include journals,…
In light of new challenges to individuals’ reproductive rights and the known challenges of clinical management of rheumatic disease patients during pregnancy, we review the current state of reproductive rheumatology and the management of patients with rheumatic disease during pregnancy.
If enacted as is, the proposed CY 2023 Medicare Physician Fee Schedule and Quality Payment Program would make significant cuts to reimbursement for evaluation and management services, creating financial instability for providers. On a positive note, it would extend some telehealth flexibilities 151 days beyond the official end of the public health emergency.
Cigna will not move forward with changes to their reimbursement policy for evaluation and management (E/M) codes submitted with modifier 25 as originally scheduled.
All ACR and ARP members are invited to apply to join colleagues and patients in Washington, D.C., on Sept. 19–20 for advocacy training and meetings with legislators to advocate on priority issues that affect rheumatology providers and patients.
As the result of years of coalition work with partners at the AMA, the ACR recently celebrated a major advocacy win when the FTC announced an investigation of PBM business practices. Join or renew your AMA membership before Sept. 1 so the ACR can keep delegate seats to drive action within the AMA.
The ACR is aware of the emerging concerns surrounding access to needed treatments, such as methotrexate, after the recent decision in Dobbs v. Jackson Women’s Health Organization. We are following this issue closely to determine if rheumatologists and rheumatology providers and patients are experiencing any widespread difficulty accessing methotrexate, and if any initial disruptions are…
Background & Objectives Worldwide, osteoarthritis (OA) is a highly prevalent, chronic joint disease that causes pain, disability and loss of function. Global trends demonstrated an increase of more than 100% in years lived with disability due to OA from 1990 to 2019. However, no nonsurgical intervention exists to prevent, halt or even delay OA progression….
Safety considerations and data sources are crucial to consider when designing studies for rheumatology treatments, according to presenters at the 2022 ACR-FDA Summit.